deltatrials
Completed PHASE1 INTERVENTIONAL 10-arm NCT02658253

Trial to Evaluate the Safety and Immunogenicity of a Placental Malaria Vaccine Candidate (PRIMVAC ) in Healthy Adults (PRIMALVAC)

Phase Ia/Ib, Randomized, Double Blinded, Dose Escalation Trial to Evaluate the Safety and Immunogenicity in Healthy European and Burkinabe Adults of a Placental Malaria Vaccine Candidate (PRIMVAC) Formulated With Alhydrogel ® or GLA-SE

Sponsor: Centre national de recherche et de formation sur le paludisme

Conditions Malaria
Updated 16 times since 2017 Last updated: Nov 26, 2025 Started: Jan 31, 2016 Primary completion: Sep 19, 2018 Completion: Feb 21, 2019
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE1 clinical study on Malaria, this trial is completed. The trial is conducted by Centre national de recherche et de formation sur le paludisme and has accumulated 16 data snapshots since 2016. Infectious disease trials contribute critical data for public health response and treatment development.

Status Flow

~Jan 2017 – ~May 2018 · 16 months · monthly snapshot~May 2018 – ~Jun 2018 · 31 days · monthly snapshot~Jun 2018 – ~Nov 2018 · 5 months · monthly snapshot~Nov 2018 – ~Dec 2018 · 30 days · monthly snapshot~Dec 2018 – ~Jan 2019 · 31 days · monthly snapshot~Jan 2019 – ~Feb 2019 · 31 days · monthly snapshot~Feb 2019 – ~Mar 2019 · 28 days · monthly snapshot~Mar 2019 – ~Dec 2019 · 9 months · monthly snapshot~Dec 2019 – ~May 2020 · 5 months · monthly snapshot~May 2020 – ~Jan 2021 · 8 months · monthly snapshot~Jan 2021 – ~Oct 2021 · 9 months · monthly snapshot~Oct 2021 – ~Jul 2024 · 33 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Mar 2025 · 6 months · monthly snapshot~Mar 2025 – ~Jan 2026 · 10 months · monthly snapshot~Jan 2026 – present · 8 months · monthly snapshot

Change History

16 versions recorded
  1. Jan 2026 — Present [monthly]

    Completed PHASE1

  2. Mar 2025 — Jan 2026 [monthly]

    Completed PHASE1

  3. Sep 2024 — Mar 2025 [monthly]

    Completed PHASE1

  4. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE1

  5. Oct 2021 — Jul 2024 [monthly]

    Completed PHASE1

Show 11 earlier versions
  1. Jan 2021 — Oct 2021 [monthly]

    Completed PHASE1

  2. May 2020 — Jan 2021 [monthly]

    Completed PHASE1

  3. Dec 2019 — May 2020 [monthly]

    Completed PHASE1

    Status: Active Not RecruitingCompleted

  4. Mar 2019 — Dec 2019 [monthly]

    Active Not Recruiting PHASE1

  5. Feb 2019 — Mar 2019 [monthly]

    Active Not Recruiting PHASE1

  6. Jan 2019 — Feb 2019 [monthly]

    Active Not Recruiting PHASE1

  7. Dec 2018 — Jan 2019 [monthly]

    Active Not Recruiting PHASE1

  8. Nov 2018 — Dec 2018 [monthly]

    Active Not Recruiting PHASE1

    Status: Unknown StatusActive Not Recruiting

  9. Jun 2018 — Nov 2018 [monthly]

    Unknown Status PHASE1

  10. May 2018 — Jun 2018 [monthly]

    Unknown Status PHASE1

    Status: RecruitingUnknown Status

  11. Jan 2017 — May 2018 [monthly]

    Recruiting PHASE1

    First recorded

Jan 2016

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Centre national de recherche et de formation sur le paludisme
  • EUCLID Clinical Trial Platform
  • European Vaccine Initiative
  • Institut National de la Santé Et de la Recherche Médicale, France
  • Recherche Clinique Paris Descartes Necker Cochin Sainte Anne
Data source: Institut National de la Santé Et de la Recherche Médicale, France

For direct contact, visit the study record on ClinicalTrials.gov .